Neutrophil Oxidative Burst Assay (DHR)
Also known as: DHR
Use
The Neutrophil Oxidative Burst Assay (DHR) is utilized to aid in screening for chronic granulomatous disease (CGD). This test measures the oxidative activity of neutrophils, which is an essential component of the immune response. Abnormal results may indicate an impairment in the respiratory burst function of neutrophils, a key feature of CGD. By comparing patient results with control samples, clinicians can determine the likelihood of CGD, aiding in diagnosis and further investigation.
Special Instructions
Not provided.
Limitations
The Neutrophil Oxidative Burst Assay has several limitations: It has not been cleared or approved by the FDA; therefore, it is a laboratory-developed test performed in a CLIA-certified lab. Variability in specimen collection or handling can impact results, making the control sample critical for context. Abnormal results without a corresponding control sample should be correlated clinically with patient symptoms, as inflammation or improper handling may introduce artifacts affecting the assay's accuracy.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
Dihydrorhodamine 123
Other
LOINC Codes
- 30903-9 - Neutrophil OB Bld Ql FC
- 11526-1 - Pathology study
Result Turnaround Time
2-3 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
1 mL
Container
Green (Sodium or Lithium Heparin) tube
Collection Instructions
Collect control specimen from a healthy individual unrelated to patient at approximately the same time as and under similar conditions to the patient.
Storage Instructions
Transport in original collection tubes at room temperature. Do not refrigerate or freeze.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | Unacceptable |
| Frozen | Unacceptable |
Other tests from different labs that may be relevant